|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The prognostic sig-nificance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive mel- anoma patients显示文摘 | van der Ploeg AP van Akkooi AC Haydu LE | 2014 | EurJ Cancer2014，50，1： | 1 |
| 2 | Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells 显示文摘 | Compton SA Elmore LW Haydu K | 2006 | Mol Cell Biol2006，26，4： | 1 |
| 3 | Distinguishing clinicopathologic features of patients with V6OOE and V6OOK BRAF-mutant metastatic melanoma 显示文摘 | Menzies AM Haydu LE Visintin L | 2012 | Clin Cancer Res2012，18，12： | 1 |
| 4 | Distinguishing clin- icopathologic features of patients with V600E and V600K BRAF- Mutant metastatic melanoma 显示文摘 | Menzies A M Haydu L E Visintin L | 2012 | Clin Cancer Res2012，18，： | 1 |
| 5 | Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib显示文摘 | Azer MW Menzies AM Haydu LE | 2014 | Cancer2014，120，4： | 1 |
| 6 | Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling显示文摘 | Chien AJ Haydu LE Biechele TL | 2014 | PLo S One2014，9，94： | 1 |
| 7 | Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells显示文摘 | Compton SA Elmore LW Haydu K | 2006 | Mol Cell Biol2006，26，4： | 1 |
| 8 | Features and management of pyre- xia with combined dabrafenib and trametinib in metastatic melanoma显示文摘 | Lee CI Menzies AM Haydu LE | 2014 | Melanoma Res2014，24，5： | 1 |
| 9 | Patterns of response and progression in patients with BRAF - mutant melanoma metastatic to the brain who were treated with dabrafenib 显示文摘 | Azer MW Menzies AM Haydu LE | 2014 | Cancer2014，120，4： | 1 |
| 10 | Mesophilic aerobic degradation of a metal lubricant by a biological consortium显示文摘 | IWASHITA S CALLAHAN T P HAYDU J | 2004 | Appl Microbiol Biotechnol2004，65，5： | 1 |
| 11 | Completeness of American Cancer Registry Treatment Data: Implications for Quality of Care Research显示文摘 | Katherine Mallin Bryan E. Palis Nancy Watroba Andrew K. Stewart Daniel Walczak Joseph Singer John Barron Wendy Blumenthal Georgette Haydu Stephen B. Edge | 2012 | Journal of the American College of Surgeons2012，，： | 1 |
| 12 | Sentinel lymph node biopsyin patients with thin primary cutaneous melanoma显示文摘 | Murali R Haydu LE Quinn MJ | 2012 | AnnSurg2012，255，1： | 1 |
| 13 | Melanoma of the Vulva and Vagi- na: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases 显示文摘 | Susan S Lauren E Haydu | 2015 | Ann Surg Oncol2015，22，6： | 1 |
| 14 | In-transit mel- anoma metastases : incidence, prognosis, and the role of lympbadenecto- my显示文摘 | Rebecca L Read Mbbs D Lauren Haydu Bsche M | 2015 | Annals of Surgical Oncology2015，22，2： | 1 |
| 15 | Economic and environmental adaptation in Florida's golf course industry: 1974--1994显示文摘 | Haydu J J Hodges A W Blokland P J | 1997 | International Turfgrass Society Research Journal1997，8，1： | 1 |
| 16 | CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions显示文摘Chimeric antigen receptor(CAR)T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma,mantle cell lymphoma,and follicular lymphoma,with multiple FDA-approved CAR T products now commercially available.Ongoing studies seek to move CAR T-cells to earlier lines of therapy and to characterize the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies including relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.Other areas of active research address CAR T in combination with other lymphoma-directed therapies,and mechanisms of CAR T resistance.This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas,management of CAR T-cell-associated toxicities,approaches to bridging therapy,and ongoing clinical trials and future research directions across a broad range of lymphoma histologies. | J.Erika Haydu Jeremy S.Abramson | 2021 | Journal of Cancer Metastasis and Treatment2021，7，1： | 0 |
| 17 | 不同商业批次花生的黄曲霉毒素水平模拟研究显示文摘为准确获知花生贸易中商业批次的黄曲霉毒素水平,本研究通过模拟应用联合国粮食及农业组织(FAO)的农业品类真菌毒素取样模型,以脱壳整粒花生批次为模拟对象,在中国、日本法规限值下,分别设置实验室样品数目、实验室样品量和接受/拒绝限值,模拟每种组合超出法规限值的接收/放行概率。结果表明,在常规黄曲霉毒素风险的产季/产地下,批次能够满足>90%概率符合中国国标和日本法规的取样方案分别为:设置接受/拒绝限值为黄曲霉毒素B15~10 ng·g^(-1),实验室样品数目和样品量分别为2~3个、5~10 kg;设置接受/拒绝限值为黄曲霉毒素总量5 ng·g^(-1),实验室样品数目和样品量分别为3个、10 kg。推荐在以下3种高风险或风险不确定情景下应用此模型制订升级取样方案、调整接收限值、增强采购/销售信心:黄曲霉毒素高风险产季/产地采购;新开发的供应商/采购区域;批次超标预警时对新批次的放行,以免连续超标。本研究结果为中国花生加工/贸易企业提供了科学取样方案,进而为保障食品安全、保护企业经济利益提供了理论参考。 | 陈尤佳 Panagiota H Tsatsos 张嘉玲 Haydu K Robert | 2024 | 核农学报2024，38，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员